

March 2014

Dear editor

Please find enclosed the revised version of our manuscript (6549-revised-2014.doc)

Title: The immunomodulatory effects of dexmedetomidine: from bench to clinic

Authors: Carlos R. Camara-Lemarroy, MD; Erick Joel Rendon-Ramirez, MD; Beatriz E. Ibarra-Yruegas, MD

Journal: World Journal of Anesthesiology

ESPS number: 6549

Response to reviewers: We are thankful for the comments, we have taken them in consideration and modified the manuscript accordingly (changes highlighted in yellow).

Reviewer 1:

- We have added a commentary on ARDS (page 12, line 5-9)
- We have inserted specific commentaries to tone down the overoptimistic sentiment (page 7, line 1, page 12 second paragraph)
- We have made the suggested grammatical/orthographic changes.
- We have changed the sentence when discussing reference 2 (Introduction, first paragraph, line 5)
- FDA approval for dexmedetomidine was 1999 (Application No.: 21-038; Approval Date:12/17/1999)

Reviewer 2:

- We have made the suggested language changes
- We have added a table (table 1) on receptor subtypes
- We have added a complete paragraph discussing side effects and potential negatives associated with dexmedetomidine (page 12, second paragraph)
- We have changed the concluding remarks to make them more reserved.

Thank you for considering our work,



Cheers

Dr. Carlos Camara-Lemarroy
UANL Hospital Universitario
Monterrey, Nuevo Leon, Mexico